NCT06343636CompletedPhase 1
A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927
Source: ClinicalTrials.gov · Last updated 7 Feb 2025
Brief summary (registry, in English)
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients with Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 115 (actual)
- First submitted
- 26 Mar 2024
- Start date
- 22 Sept 2023
- Primary completion date
- 10 Jan 2025
- Lead sponsor
- Vigil Neuroscience, Inc.
- Diseases
- Alzheimer disease
- NCT number
- NCT06343636
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 115
- From 22 Sept 2023 to the primary completion date, 10 Jan 2025
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The participant has any concurrent disease or condition that, in the opinion of the principal investigator, would make the participant unsuitable for participation in the clinical study
Who the study is looking for
- The participant is deemed healthy by the principal investigator, as determined by prestudy medical evaluation
- The participant voluntarily agrees to participate in this study and signs an institutional review board approved informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nucleus Network Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
| K2 Medical Research Coordinator of this site? Confirm its status | Maitland | United States | Unknown status |
| Clinical Pharmacology of Miami Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.